Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19

• Autori principali: Xiaomei I. Liu (Autore), André Dallmann (Autore), Kristina Brooks (Autore), Brookie M. Best (Autore), Diana F. Clarke (Autore), Mark Mirochnick (Autore), John N. van denAnker (Autore), Edmund V. Capparelli (Autore), Jeremiah D. Momper (Autore)
• Natura: Libro
• Pubblicazione: Wiley, 2023-02-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Pregnant individuals are at high risk for severe illness from COVID‐19, and there is an urgent need to identify safe and effective therapeutics for this population. Remdesivir (RDV) is a SARS‐CoV‐2 nucleotide analog RNA polymerase inhibitor. Limited RDV pharmacokinetic (PK) and safety data...